ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1418

External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab

Isabelle Koné-Paut1, Maryam Piram2, Susanne Benseler3, Jasmin B. Kuemmerle-Deschner4, Annette F. Jansson5, Itzhak Rosner6, Alberto Tommasini7, Sara Murias8, Omer Karadag9, Jeremy Levy10, Serge Smeets11 and Fabrizio De Benedetti12, 1APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, 2Pediatrics, APHP, CHU de Bicêtre, University of Paris SUD, Paris, France, 3Alberta Children's Hospital, Calgary, AB, Canada, 4Pediatrics, University Hospital Tübingen, Tübingen, Germany, 5Ludwig Maximilian University, Munich, Germany, 6Bnai-Zion Medical Center, Haifa, Israel, 7Department of Internal Medicine, Università Cattolica Sacro Cuore, Rome, Italy, 8Hospital Infantil La Paz, Madrid, Spain, 9Rheumatology, Hacettepe University, Faculty of Medicine, Ankara, Turkey, 10BIOP, Reinach, AR, Switzerland, 11Novartis Pharma B.V., Arnhem, Netherlands, 12IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: canakinumab, Familial Mediterranean fever and interleukins (IL), Traps

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: AIDAI is a novel and unique, validated patient (pt)-reported assessment tool to evaluate disease activity in familial Mediterranean fever (FMF), hyper-IgD syndrome/mevalonate kinase deficiency (HIDS/MKD) and TNF receptor-associated periodic syndrome (TRAPS).1 Here we performed an external validation of AIDAI by calculating scores over 40 weeks (wks) of canakinumab (CAN) treatment in pts enrolled into the CLUSTER trial (NCT02059291) and assessed correlation between AIDAI and disease/response characteristics.

 

Methods: CLUSTER consisted of one cohort per disease (crFMF, HIDS/MKD and TRAPS).2 AIDAI was calculated as the sum of 12 items (Yes=1; No=0)1 for 30 consecutive days. AIDAI score was calculated if the first score was recorded before ≥29 days. Missing items beyond last evaluable measurement were imputed by last observation carried forward (LOCF). Inactive disease (ID) was defined as AIDAI score <9. Correlation analysis of AIDAI with Sheehan disability score (SDS), child health questionnaire–psychological/physical (CHQ–PsCS/PCS), physician global assessment (PGA), short form 12–physical/mental component summaries (SF12–PCS/MCS), C-reactive protein (CRP), and serum amyloid A (SAA) were performed. Significance was set at p<0.05.

 

Results: Overall, 167 (crFMF: N=59; HIDS/MKD: N=66; TRAPS: N=42) pts were randomized to CAN 150 mg or placebo every 4 wks. Median AIDAI scores in all 3 cohorts decreased from baseline (BL) to Wk 16 (crFMF: 22.5 to 5.0; HIDS/MKD: 41.5 to 12.0; TRAPS: 89.0 to 13.0) and through Wk 40 (crFMF: 1.0; HIDS/MKD: 5.0; TRAPS: 20.5; Fig 1). In all 3 cohorts, the proportion of pts with ID (AIDAI score <9) was higher at Wk 40 versus BL (crFMF: 69.5% vs 5.1%; HIDS/MKD: 56.1% vs 6.1%; TRAPS: 42.9% vs 2.4%). AIDAI at Wk 40 correlated significantly with: SDS in all 3 cohorts; CHQ-PsCS in crFMF and HIDS/MKD; CHQ-PCS in crFMF; PGA in TRAPS; SF12–PCS in crFMF and TRAPS. SF12-MCS, CRP, and SAA did not correlate with AIDAI (Table 1). 

Conclusion: AIDAI scores decreased markedly over 40 weeks of treatment with canakinumab in crFMF, HIDS/MKD and TRAPS, with a relevant percentage of patients having inactive disease score. AIDAI improvements at Week 40 correlated with patient- and physician-driven evaluations. AIDAI is a validated patient-reported tool to assess disease activity and appears to have good sensitivity to change to be used in comparative trials. Patient’s experience on disease activity does not strictly correlate with CRP and SAA, as these reflect more closely biological inflammation than clinical symptoms.

 

References: 1. Piram M, et al. Ann Rheum Dis. 2014;73:2168-73. 2. De Benedetti F, et al. NEJM. 2018;378:1908-19.


Disclosure: I. Koné-Paut, None; M. Piram, Novartis, Pfizer, Abbvie, 5,Novartis, 8; S. Benseler, Novartis, SOBI, AbbVie, 5; J. B. Kuemmerle-Deschner, Novartis, 2,Novartis, SOBI, 5; A. F. Jansson, Novartis, 2; I. Rosner, None; A. Tommasini, None; S. Murias, None; O. Karadag, None; J. Levy, Novartis, 5; S. Smeets, Novartis, 3; F. De Benedetti, Novartis, Roche, Pfizer, SOBI, AbbVie, Novimmune, BMS, Sanofi, 2.

To cite this abstract in AMA style:

Koné-Paut I, Piram M, Benseler S, Kuemmerle-Deschner JB, Jansson AF, Rosner I, Tommasini A, Murias S, Karadag O, Levy J, Smeets S, De Benedetti F. External Validation of the Autoinflammatory Disease Activity Index (AIDAI) in Patients with Colchicine-Resistant FMF, Hids/Mkd, and TRAPS: Results from a Pivotal, Phase 3 Trial of Canakinumab [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/external-validation-of-the-autoinflammatory-disease-activity-index-aidai-in-patients-with-colchicine-resistant-fmf-hids-mkd-and-traps-results-from-a-pivotal-phase-3-trial-of-canakinumab/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/external-validation-of-the-autoinflammatory-disease-activity-index-aidai-in-patients-with-colchicine-resistant-fmf-hids-mkd-and-traps-results-from-a-pivotal-phase-3-trial-of-canakinumab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology